Literature DB >> 30152746

Residual Disease after Neoadjuvant Therapy for Breast Cancer: Can MRI Help?

Nola M Hylton1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30152746      PMCID： PMC6209065          DOI： 10.1148/radiol.2018181846

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   11.105


× No keyword cloud information.
  6 in total

1.  Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

Authors:  Jennifer F De Los Santos; Alan Cantor; Keith D Amos; Andres Forero; Mehra Golshan; Janet K Horton; Clifford A Hudis; Nola M Hylton; Kandace McGuire; Funda Meric-Bernstam; Ingrid M Meszoely; Rita Nanda; E Shelley Hwang
Journal:  Cancer       Date:  2013-02-21       Impact factor: 6.860

2.  MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?

Authors:  Kandace P McGuire; Jorge Toro-Burguete; Hang Dang; Jessica Young; Atilla Soran; Margarita Zuley; Rohit Bhargava; Marguerite Bonaventura; Ronald Johnson; Gretchen Ahrendt
Journal:  Ann Surg Oncol       Date:  2011-09-27       Impact factor: 5.344

3.  Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.

Authors:  Gorane Santamaría; Xavier Bargalló; Pedro Luis Fernández; Blanca Farrús; Xavier Caparrós; Martin Velasco
Journal:  Radiology       Date:  2016-11-22       Impact factor: 11.105

4.  Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy.

Authors:  Soo-Yeon Kim; Nariya Cho; In-Ae Park; Bo Ra Kwon; Sung Ui Shin; Soo Yeon Kim; Su Hyun Lee; Jung Min Chang; Woo Kyung Moon
Journal:  Radiology       Date:  2018-08-28       Impact factor: 11.105

5.  Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis.

Authors:  Michael L Marinovich; Petra Macaskill; Les Irwig; Francesco Sardanelli; Eleftherios Mamounas; Gunter von Minckwitz; Valentina Guarneri; Savannah C Partridge; Frances C Wright; Jae Hyuck Choi; Madhumita Bhattacharyya; Laura Martincich; Eren Yeh; Viviana Londero; Nehmat Houssami
Journal:  BMC Cancer       Date:  2015-10-08       Impact factor: 4.430

Review 6.  Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials.

Authors:  Raquel F D van la Parra; Henry M Kuerer
Journal:  Breast Cancer Res       Date:  2016-03-08       Impact factor: 6.466
  6 in total
  2 in total

1.  Visual Evaluation of Ultrafast MRI in the Assessment of Residual Breast Cancer after Neoadjuvant Systemic Therapy: A Preliminary Study Association with Subtype.

Authors:  Maya Honda; Masako Kataoka; Mami Iima; Rie Ota; Akane Ohashi; Ayami Ohno Kishimoto; Kanae Kawai Miyake; Marcel Dominik Nickel; Yosuke Yamada; Masakazu Toi; Yuji Nakamoto
Journal:  Tomography       Date:  2022-06-10

2.  Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?

Authors:  Bruna M Thompson; Luciano F Chala; Carlos Shimizu; Max S Mano; José R Filassi; Felipe C Geyer; Ulysses S Torres; Giselle Guedes Netto de Mello; Cláudia da Costa Leite
Journal:  Eur Radiol       Date:  2021-10-30       Impact factor: 7.034
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.